
AbstractBackground: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive...
Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Front Cardiovasc Med
AbstractBackground: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive...
Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Front Cardiovasc Med
AbstractBackground: We evaluated the value of pre-treatment positron-emission tomography-computed tomography...
Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)
AbstractBackground: Histological characteristics at the invasive front may reflect tumor aggressiveness;...
Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Annals of oncology
AbstractBackground and objective: Longitudinal analysis of patient-reported outcome (PRO) data remains challenging,...
Posté par : Mr. Antoine FALCOZ
Nom de la revue : Comput Methods Programs Biomed
AbstractAim: A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of...
Posté par : Mr. Antoine FALCOZ, Dr. Guillaume MOUILLET
Nom de la revue : Qual Life Res
AbstractIntroduction - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical...
Posté par : Dr. Guillaume MOUILLET, Mr. Antoine FALCOZ, Mme. Joëlle FRITZSCH, , , Dr. Sophie PAGET-BAILLY
Nom de la revue : Quality of Life Research
AbstractBackground: Randomized controlled trials (RCTs) represent the best evidence in oncology research....
Posté par : Mr. Antoine FALCOZ, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY
Nom de la revue : Neurooncol Pract
AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...
Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol